Key Developments: Arena Pharmaceuticals Inc (ARNA.O)

ARNA.O on Nasdaq

4 Aug 2015
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Arena Pharmaceutical announces appointment of CFO - Form 8-K
Thursday, 9 Jul 2015 05:16pm EDT 

Arena Pharmaceutical Inc:Appoints Jack Lief, President and Chief Executive Officer as the Principal Financial Officer effective July 10.  Full Article

Arena Pharmaceuticals announces departure of chief financial officer
Tuesday, 16 Jun 2015 04:30pm EDT 

Arena Pharmaceuticals Inc:Says Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer, has decided to leave the company.Hoffman is expected to remain in his current role at Arena until July 10, 2015.  Full Article

Arena Pharmaceuticals Inc's Arena Pharmaceuticals GmbH and Roivant Sciences enter into collaboration for nelotanserin
Monday, 11 May 2015 04:01pm EDT 

Arena Pharmaceuticals Inc:Says its subsidiary, Arena Pharmaceuticals GmbH and Roivant Sciences Ltd, have entered into a development, marketing and supply agreement for nelotanserin, Arena's internally discovered inverse agonist of 5-HT2A receptor.Agreement grants Roivant exclusive worldwide rights to develop and commercialize nelotanserin.  Full Article

Arena Pharmaceuticals Inc reports favorable results from Phase 1 single-ascending dose clinical trial of APD371
Wednesday, 29 Apr 2015 08:00am EDT 

Arena Pharmaceuticals Inc:Says favorable results from Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent agonist of cannabinoid 2 (CB2) receptor currently in development for treatment of pain and potentially fibrotic diseases.Randomized, double-blind and placebo-controlled Phase 1 clinical trial enrolled 56 healthy adults to evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD371.Dose responsive exposure was observed over the explored dose range of 10-400 mg with good tolerability at all doses administered.  Full Article

Arena Pharmaceuticals Inc receives additional patent for BELVIQ
Tuesday, 7 Apr 2015 08:00am EDT 

Arena Pharmaceuticals Inc:Says US Patent and Trademark Office granted Arena US Patent No. 8,999,970, which describes method for selecting appropriate patients based on renal function for BELVIQ (lorcaserin HCl), a serotonin 2C receptor agonist approved for weight management.In addition to this method-of-treatment patent, composition of matter patents for BELVIQ are issued in major jurisdictions globally that, in most cases, are capable of continuing into 2023.Arena has filed applications for patent term extension on patents directed to composition of matter in U.S, which, if granted, would extend the composition of matter patent term for BELVIQ into 2026 or potentially 2027.  Full Article

Arena Pharmaceuticals announces marketing approval in South Korea of BELVIQ (lorcaserin HCl) for weight management
Tuesday, 3 Feb 2015 05:00am EST 

Arena Pharmaceuticals Inc:Says Ildong Pharmaceutical Co., Ltd., has informed Arena that the Ministry of Food and Drug Safety has approved BELVIQ (lorcaserin HCl) for marketing for weight management in South Korea.Says Ildong will market and distribute BELVIQ in South Korea under its marketing and supply agreement with Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, or Arena GmbH. In connection with the approval, Arena GmbH will receive a payment of $3.0 mln from Ildong.  Full Article

Arena Pharmaceuticals announces public offering of common stock
Tuesday, 20 Jan 2015 04:04pm EST 

Arena Pharmaceuticals:Intends to offer and sell shares of its common stock in an underwritten public offering.All of the shares are being offered by Arena.Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering.  Full Article

Arena Pharmaceuticals initiates phase 2 clinical trial evaluating ralinepag for Pulmonary Arterial Hypertension
Monday, 12 Jan 2015 08:00am EST 

Arena PharmaceuticalsInc:Says initiation of patient dosing in a Phase 2 clinical trial of ralinepag, an oral, non-prostanoid prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH).This 22-week, randomized, double-blind and placebo-controlled Phase 2 trial will evaluate the hemodynamic and exercise capacity effects, safety and tolerability of ralinepag in up to 60 patients with PAH.During the first nine weeks of the trial, patients will be titrated to their individual tolerance level, and then sustained at this level for remainder of the trial.  Full Article

Arena Pharmaceuticals Inc announces positive results from Phase 1b Clinical Trial
Wednesday, 7 Jan 2015 08:00am EST 

Arena Pharmaceuticals Inc:Says Top-line results from a Phase 1b multiple ascending dose clinical trial for APD334, an oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases.In the Phase 1b clinical trial, APD334 demonstrated a dose-dependent effect on lymphocyte count lowering in blood, with mean decreases from baseline of up to 69%. Lymphocyte counts, on average, recovered to baseline within one week of conclusion of dosing.There were no clinically significant safety findings with respect to heart rate or rhythm or pulmonary function, and no clinically significant elevations in liver enzyme tests.The most common treatment-emergent adverse events were mild or moderate contact dermatitis, headache, constipation and diarrhea, with none being clearly drug related.There were no discontinuations for adverse events, and no serious adverse events were observed.  Full Article

Arena Pharmaceuticals issued composition of matter patent by United States Patent and Trademark Office for Ralinepag and Related Compounds
Tuesday, 25 Nov 2014 08:00am EST 

Arena Pharmaceuticals Inc:Says that US Patent and Trademark Office granted Arena U.S. Patent No. 8,895,776, entitled Modulators of the Prostacyclin (PGI2) Receptor Useful for Treatment of disorders related Thereto, covering ralinepag (formerly APD811), an orally available agonist of the prostacyclin (IP) receptor.Ralinepag is an investigational drug candidate being developed by Arena for the treatment of vasospastic diseases such as pulmonary arterial hypertension (PAH).Arena owns patents and pending patent applications covering compositions of matter for ralinepag and related compounds, as well as methods of treatment utilizing ralinepag and related compounds.Patent applications for ralinepag have been filed in 19 jurisdictions, including the United States, Europe, Japan and China.  Full Article

Search Stocks